Hdlq66^NZB/BlNJ
QTL Variant Detail

Summary

• QTL variant: Hdlq66^NZB/BlNJ
• Name: HDL QTL 66; NZB/BlNJ
• MGI ID: MGI:5636010
• QTL: Hdlq66 Location: unknown Genetic Position: Chr5, Syntenic

Variant origin

• Strain of Specimen: NZB/BlNJ

Variant description

• Allele Type: QTL

Notes

Mapping and Phenotype information for this QTL, its variants and associated markers

J:154142

A backcross (NZO/HlLt x NON/LtJ) x NON/LtJ, and three intercrosses, (C57BL/6J x DBA/2J), (C57BL/6J x C3H/HeJ), and (NZB/B1NJ x NZW/LacJ) were informative in mapping QTL loci controlling plasma HDL , total cholesterol and triglyceride levels.

In the (C57BL/6J x DBA/2J) cross QTL results presented here by Phenotype, Chr, Marker, cM location , LOD, High strain

Plasma HDL , Chr 1 , Hdlq15 , 85cM , 2.8 , DBA/2J

Plasma HDL , Chr 3 , Hdlq21 , 64cM , 3.0 , C57BL/6J

Plasma HDL , Chr 4 , Hdlq64 , 3cM , 2.2 , C57BL/6J

Plasma HDL , Chr 6 , Hdlq11 , 37cM , 2.8 , DBA/2J

Plasma HDL , Chr 8 , Hdlq16 , 56cM , 4.6 , DBA/2J

Plasma HDL , Chr 12, Hdlq63 , 42cM , 2.2 , C57BL/6J

12.09.2014 Curator Note:

Because Hdlq15 was was originally mapped in J:88486 in 2004 using an (C57BL/6J x 129S1/SvImJ)F2 intercross, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq87.

Because Hdlq21 was originally mapped inJ:89309 in 2004 using an (SM/J x NZB/BlNJ)F2 intercross, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq93.

Because Hdlq64 was originally mapped in J:142770 in 2008 using (DBA/1J x DBA/2J) crosses, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq98.

Because Hdlq11 was originally mapped in J:83460 in 2003 using a (CAST/Ei x DBA/2J)F2 cross, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq85.

Because Hdlq16 was originally mapped in J:88486 in 2004 using an (C57BL/6J x 129S1/SvImJ)F2 intercross, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq88.

Because Hdlq63 was originally mapped in J:142770 in 2008 using (DBA/1J xDBA/2J)crosses, which differs from the cross used here, we consider the current study a separate mapping experiment and have named the QTL Hdlq97.

In the (C57BL/6J x C3H/HeJ) cross

Plasma HDL , Chr 1 , Hdlq15 , 6.0cM 9.1, C3H/HeJ

Plasma HDL , Chr 11 , Hdlq74 , 42cM ,3.2, C3H/HeJ

Plasma HDL , Chr 18 , Hdlq76,37cM ,2.1, C3H/HeJ

Plasma HDL , Chr 19 , Hdlq48 , 4cM ,2.1, C57BL/6J

In the (NZO/HlLt x NON/LtJ) x NON/LtJ cross

PlaDL , Chr1 ,Hdlq69 , 92cM , 2.4 , NON/LtJ

Plasma HDL , Chr 5 , Hdlq73, 41cM , 3.4, Heterozygous

In the (NZB/B1NJ x NZW/LacJ) cross

Plasma HDL , Chr 1 , Hdlq68 , 49cM , 3.3 , NZW/LacJ

Plasma HDL , Chr 2 , Hdlq70 , 82cM , 2.8 , NZB/B1

PlasmaHDL , Chr3 , Hdlq71 , 26cM , 4.5 , NZB/B1NJ

Plasma HDL , Chr 4 , Hdlq72 , 25cM , 3.5 , NZW/LacJ

Plasma HDL ,Chr 5 , Hdlq7 , 26cM , 9.05 , NZW/LacJ

Plasma HDL , Chr 5 , Hdlq8 , 57cM , 12.7 , NZB/B1NJ

Plasma HDL , Chr 12 , Hdlq75 , 54cM , 4.1 , NZB/B1NJ

Plasma HDL , Chr 16 , Hdlq76 , 2cM , 3.2 , NZW/LacJ

Plasma HDL , Chr 18 , Hdlq77 , 30cM,5.1 , NZW/LacJ

12.09.2014 Curator Note: Because Hdlq7 was originally mapped in J:84430 in 2003 using a (C57BL/6J x NZB/BlNJ)F1 x C57BL/6J backcross, which differs from the cross used here, we consider the current study a separate mapping experiment and have named this QTL Hdlq66.

Also, because Hdlq76 was first mapped here to Chr 18 using the C57BL/6J x C3H/HeJ cross; we have renamed the QTL mapping to 2cM on Chr16 using the (NZB/B1NJ x NZW/LacJ) cross as Hdlq101. We consider the separate crossesasseparte map experiments, mapping novel QTL.

In the (C57BL/6J x DBA/2J) cross

Triglycerides , Chr 12 , Tgq33 , 14 cM , 3.1 , C57BL/6

In the (C57BL/6J x C3H/HeJ) cross

Triglycerides , Chr 2 , Tgq32 , 80 cM , 4.7 , C3H/HeJ

Triglycerides , Chr19 , Tgq34 , 39 cM , 3.2 , C3H/HeJ

In the (NZO/HlLt x NON/LtJ) x NON/LtJ Cross

Triglycerides , Chr 1 , Tgq30 , 89 cM , 3.5 , NON/LtJ

Triglycerides , Chr 2 , Tgq31 , 73 cM , 2.4 , NON/LtJ

In the(NZB/B1NJ x NZW/LacJ) cross

Triglycerides , Chr 7, Tgq4, 50cM ,3.1 , NZW/LacJ

Triglycerides , Chr 8 , Tgq5 , 11 cM , 3.2 , NZW/LacJ

Triglycerides , Chr 18 , Tgq6 ,34 cM,1 , NZW/LacJ

In the (C57BL/6J x C3H/HeJ) cross

Total Cholesterol , Chr 1 , Tcq3, 84 , 2.2, C3H/HeJ

In the(NZO/HlLt x NON/LtJ) x NON/LtJ cross

Total Cholesterol , Chr 8 , Tcq7 , 36 , 1.5 , Heterozygous

In the (NZB/B1NJ x NZW/Lac) cholesterol , Chr2 , Tcq4 , 83,4.0 , NZB/B1NJ

Total Cholesterol , Chr 5 , Tcq5 , 61 , 7.9 ,NZB/B1NJ

Total Cholesterol , Chr 7 , Tcq6 , 62 , 2.9 , NZW/LacJ

Total Cholesterol , Chr 9 , Tcq8 , 53 , 7.7 , NZB/B1NJ

Total Cholesterol , Chr 18 , Tcq9 , 33 , 5.8, NZB/B1NJ

References

• Original: J:154142 Su Z, et al., Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene. J Lipid Res. 2009 May 12;50:2083-2094
• All: 1 reference(s)